Surgical margin status and role of adjuvant therapy in human papillomavirus-positive oropharyngeal cancer.
Young Min ParkJae-Yol LimYoon Woo KohEun Chang ChoiSe-Heon KimPublished in: Head & neck (2023)
In T1-T2 lesions without other risk factors, even with a safety margin ≥1 mm, adjuvant therapy can potentially be omitted. Adjuvant therapy can significantly reduce disease recurrence in HPV+ OPSCC patients with risk factors.